The U.S. Food and Drug Administration approved Aduhelm for the treatment of Alzheimer’s. Researchers evaluated Aduhelm’s efficacy in three separate studies representing a total of 3,482 patients. It is the first approved treatment to attack the disease process of Alzheimer’s instead of just addressing dementia symptoms.
Dr. Aileen Marty, Infectious Disease Specialist & Professor at Florida International University joined Bob Sirott to talk about the new drug and its mixed reviews and concerns about the data. In addition, she shares insight on the Delta variant that scientists believe is more transmissible or can cause more severe disease.